Axsome Therapeutics (AXSM) Accounts Payables (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Accounts Payables data on file, last reported at $106.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 24.57% year-over-year to $106.7 million; the trailing twelve-month figure through Mar 2026 stood at $106.7 million (up 24.57% YoY), and the FY2025 full-year result was $65.5 million, down 8.97% from the prior year.
• Accounts Payables rose to $106.7 million in Q1 2026, from $65.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $106.7 million in Q1 2026 to a low of $12.6 million in Q1 2022.
• A 5-year average of $52.2 million and a median of $53.8 million in 2024 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables soared 193.59% in 2022 and fell 15.6% in 2025, its largest moves.
• Tracing AXSM's Accounts Payables over 5 years: stood at $38.6 million in 2022, then advanced by 5.37% to $40.7 million in 2023, then jumped by 76.99% to $72.0 million in 2024, then slipped by 8.97% to $65.5 million in 2025, then jumped by 62.81% to $106.7 million in 2026.
• Business Quant data shows AXSM's Accounts Payables at $106.7 million in Q1 2026, $65.5 million in Q4 2025, and $54.2 million in Q3 2025.